School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, United Kingdom.
J Control Release. 2018 Jan 10;269:136-147. doi: 10.1016/j.jconrel.2017.11.013. Epub 2017 Nov 10.
There remains an unmet dermatological need for innovative topical agents that achieve better longterm outcomes with fewer side effects. Modulation of the expression and activity of microRNA (miRNAs) represents an emerging translational framework for the development of such innovative therapies because changes in the expression of one miRNA can have wide-ranging effects on diverse cellular processes associated with disease. In this short review, the roles of miRNA in epidermal development, psoriasis, cutaneous squamous cell carcinoma and re-epithelisation are highlighted. Consideration is given to the delivery of oligonucleotides that mimic or inhibit miRNA function using vehicles such as cell penetrating peptides, spherical nucleic acids, deformable liposomes and liquid crystalline nanodispersions. Formulation of miRNA-directed oligonucleotides with such skin-penetrating epidermal agents will drive the development of RNA-based cutaneous therapeutics for deployment as primary or adjuvant therapies for epidermal disorders.
目前,人们仍然需要创新的局部治疗药物,以较少的副作用获得更好的长期效果。微 RNA(miRNA)表达和活性的调节代表了开发此类创新疗法的一个新兴转化框架,因为 miRNA 表达的变化可能对与疾病相关的多种细胞过程产生广泛影响。在这篇简短的综述中,突出了 miRNA 在表皮发育、银屑病、皮肤鳞状细胞癌和再上皮化中的作用。本文还考虑了使用穿透细胞肽、球形核酸、可变形脂质体和液晶纳米分散体等载体来递呈模拟或抑制 miRNA 功能的寡核苷酸。将 miRNA 导向的寡核苷酸与这些具有皮肤穿透性的表皮试剂联合应用,将推动 RNA 为基础的皮肤治疗药物的开发,作为表皮疾病的一线或辅助治疗药物。